AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30663593 — intervention group
Group type: COMPARATOR
Intervention: Vincristine 1·4 mg/m2 [maximum 2·0 mg]
Number of subjects: 0
Study 27866713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis (n=42)
Number of subjects: 100
Study 27866713 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with laparoscopy alone (n=31)
Number of subjects: 100
Study 27866713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 27423289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral TAP block with bupivacaine
Number of subjects: 40
Study 27423289 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 40
Study 23112275 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable synthetic polyurethane foam (BSPF)
Number of subjects: 68
Study 23112275 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intranasal septal splint (INS)
Number of subjects: 68
Study 23112275 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 68
Study 21646588 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization navigator intervention (immunization tracking, reminder/recall, home visits)
Number of subjects: 7546
Study 21646588 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 7546
Study 19736359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride therapy for 6 months
Number of subjects: 361
Study 19736359 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 361
Study 19736359 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked improvement in depression (Clinical Global Impression-Improvement subscale score of 1)
Number of subjects: 361
Study 17034955 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 8 weeks
Number of subjects: 98
Study 17034955 — intervention group
Group type: EXPERIMENTAL
Intervention: BclI polymorphism carriers
Number of subjects: 98
Study 17034955 — intervention group
Group type: EXPERIMENTAL
Intervention: BclI carriers in high ACTH tertile
Number of subjects: 98
Study 12759221 — intervention group
Group type: EXPERIMENTAL
Intervention: TPNGLN (glutamine-supplemented TPN, 0.4 g.kg‐1.day‐1)
Number of subjects: 19
Study 12759221 — intervention group
Group type: COMPARATOR
Intervention: TPN (conventional parenteral nutrition)
Number of subjects: 19
Study 12759221 — intervention group
Group type: COMPARATOR
Intervention: TPNGLN
Number of subjects: 19
Study 12759221 — intervention group
Group type: EXPERIMENTAL
Intervention: TPNGLN + GH/IGF‐I (GH 0.2 IU.kg‐1.day‐1 and IGF‐I 160 microg.kg‐1.day‐1)
Number of subjects: 19
Study 11020677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 74
Study 11020677 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate 50 mg
Number of subjects: 74
Study 9545747 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colon resection
Number of subjects: 1500
Study 9545747 — intervention group
Group type: COMPARATOR
Intervention: Open colon resection
Number of subjects: 1500
Study 8290465 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine alcoholic solution
Number of subjects: 0
Study 8290465 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine aqueous solution
Number of subjects: 0
Study 3984975 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium loading dose of 550 mg
Number of subjects: 45
Study 3984975 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium therapy
Number of subjects: 45
Study 31564004 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 103
Study 31564004 — intervention group
Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 103
Study 30348154 — intervention group
Group type: COMPARATOR
Intervention: Fluorescent dusts treated inserts
Number of subjects: 0
Study 27595104 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture F_1
Number of subjects: 150
Study 27595104 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture F_2
Number of subjects: 150
Study 27595104 — intervention group
Group type: COMPARATOR
Intervention: Placebo F_3
Number of subjects: 150
Study 24874781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-targeted intervention using the 5As approach
Number of subjects: 319
Study 24874781 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 clinicians
Number of subjects: 319
Study 24874781 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 clinicians
Number of subjects: 319
Study 21210268 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol drops applied topically with standard therapy (topical clotrimazole)
Number of subjects: 84
Study 21210268 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard therapy (topical clotrimazole)
Number of subjects: 84
Study 16142002 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel containing gaïazulene and dimeticone
Number of subjects: 233
Study 16142002 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 233
Study 12483625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum feeding
Number of subjects: 56
Study 12483625 — intervention group
Group type: COMPARATOR
Intervention: Traditional feeding protocol
Number of subjects: 56
Study 12483625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 9536918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild indirect cooling (cool water immersion at 16 degrees C for 2 min, 6 times)
Number of subjects: 90
Study 7897032 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially competent children and their mothers
Number of subjects: 0
Study 7897032 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive children and their mothers
Number of subjects: 0
Study 7897032 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious children and their mothers
Number of subjects: 0
Study 2694314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 198
Study 2694314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 150 mcg/kg
Number of subjects: 198
Study 2694314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 198
Study 2694314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 367511 — intervention group
Group type: EXPERIMENTAL
Intervention: naftidrofuryl
Number of subjects: 91
Study 367511 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 29448072 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 875
Study 29448072 — intervention group
Group type: COMPARATOR
Intervention: TRZ
Number of subjects: 875
Study 27223689 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to preferred music for 30-45 minutes per night for 3 months)
Number of subjects: 64
Study 27223689 — intervention group
Group type: COMPARATOR
Intervention: Control group (received sleep hygiene education and biweekly telephone calls)
Number of subjects: 64
Study 27223689 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 64
Study 27223689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 25536517 — intervention group
Group type: EXPERIMENTAL
Intervention: Task‐oriented visual feedback balance training
Number of subjects: 39
Study 24167769 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral calibration
Number of subjects: 88
Study 24167769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon (injections and tablets)
Number of subjects: 0
Study 20695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol (metabolic hepatoprotector with antioxidant activity)
Number of subjects: 0
Study 20695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with immunomodulators (including cycloferon, galavit, and derinat)
Number of subjects: 0
Study 18156372 — intervention group
Group type: EXPERIMENTAL
Intervention: Free spectacles (arm A)
Number of subjects: 6904
Study 18156372 — intervention group
Group type: COMPARATOR
Intervention: Prescription only (arm B)
Number of subjects: 6904
Study 16785215 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-triggered (ST) dosing of lorazepam based on CIWA-Ar score
Number of subjects: 183
Study 16785215 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule (FS) dosing of lorazepam with tapering over 4 days
Number of subjects: 183
Study 14605453 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconventional anti-cancer drugs
Number of subjects: 30000
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids administered within the first 2 weeks of life
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and inhaled bronchodilators
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis against respiratory syncytial virus
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human superoxide dismutase
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 proteinase inhibitor
Number of subjects: 0
Study 10830255 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous surfactant
Number of subjects: 0
Study 8633942 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 102
Study 8633942 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit
Number of subjects: 102
Study 1727807 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg MEL administered daily (days 1-30) for 4 months
Number of subjects: 32
Study 1727807 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg MEL (days 5-17) and 75 mg MEL combined with 0.3 mg NET
Number of subjects: 32
Study 6371876 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50-200 mg once daily for 5 weeks
Number of subjects: 40
Study 6371876 — intervention group
Group type: COMPARATOR
Intervention: Doxepin 25-100 mg once daily for 5 weeks
Number of subjects: 40
Study 29577843 — intervention group
Group type: EXPERIMENTAL
Intervention: Moms' Empowerment Program (MEP), a 10-week group intervention
Number of subjects: 72
Study 29577843 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison condition
Number of subjects: 72
Study 28971855 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPP as a pretraining warm-up
Number of subjects: 408
Study 28971855 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPP as a post-training cool-down
Number of subjects: 408
Study 28971855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 408
Study 28971855 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPP warm-up vs CIPP cool-down
Number of subjects: 408
Study 28971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the intervention
Number of subjects: 408
Study 30024240 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation of showing vulnerability
Number of subjects: 7
Study 30024240 — intervention group
Group type: EXPERIMENTAL
Intervention: Other-evaluation of showing vulnerability
Number of subjects: 7
Study 30024240 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of construal
Number of subjects: 7
Study 26791822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group of 4 late-adolescent males (ages 18-22)
Number of subjects: 4
Study 26791822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group of 3 late-adolescent males with 1 slightly older adult (age 25-30)
Number of subjects: 4
Study 26791822 — intervention group
Group type: COMPARATOR
Intervention: Adolescents tested alone
Number of subjects: 4
Study 24676877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasisulam sodium (targeting an albumin‐corrected exposure of 1200‐6400 h.μg/mL on day 1)
Number of subjects: 336
Study 24676877 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m² on days 1, 8, and 15 every 28 days)
Number of subjects: 336
Study 22409642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anglicized Battlemind intervention
Number of subjects: 2443
Study 22409642 — intervention group
Group type: COMPARATOR
Intervention: U.K. standard postdeployment brief
Number of subjects: 2443
Study 20178538 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted cervical cancer vaccine
Number of subjects: 354
Study 20178538 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide placebo
Number of subjects: 354
Study 18622257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9624
Study 18622257 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 9624
Study 16101180 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 i.v. followed by irinotecan 200 mg/m2 i.v. on day 1 with rhG-CSF support from days 2 to 6, every 3 weeks
Number of subjects: 31
Study 16101180 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus irinotecan with rhG-CSF support
Number of subjects: 31
Study 11834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Treatment (ST)
Number of subjects: 74
Study 11834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir Treatment (CT)
Number of subjects: 74
Study 11834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-Cidofovir Treatment (SCT)
Number of subjects: 74
Study 11834957 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus DNA Clearance
Number of subjects: 74
Study 9893183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sulfite red and white wines
Number of subjects: 16
Study 9893183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sulfite white wine
Number of subjects: 16
Study 9893183 — intervention group
Group type: COMPARATOR
Intervention: Placebo wines
Number of subjects: 16
Study 7717184 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 20
Study 7717184 — intervention group
Group type: EXPERIMENTAL
Intervention: PETN (150 mg b.i.d.)
Number of subjects: 20
Study 7717184 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Controls)
Number of subjects: 20
Study 2149509 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (nasal spray, 3 daily doses of 400 micrograms) combined with cyproterone acetate (CPA, 3 daily doses of 50 mg orally for 2 weeks)
Number of subjects: 367
Study 2149509 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy (standard androgen-deprivative therapy)
Number of subjects: 367
Study 6775537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (4%)
Number of subjects: 11
Study 6775537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31685797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan oligosaccharide (GO2KA1)
Number of subjects: 0
Study 31685797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28457876 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patient (SP) training
Number of subjects: 29
Study 28457876 — intervention group
Group type: COMPARATOR
Intervention: Live patient (LP) training
Number of subjects: 29
Study 25479571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g protein per kg body weight per day
Number of subjects: 39
Study 25479571 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g protein per kg body weight per day
Number of subjects: 39
Study 25479571 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g protein per kg body weight per day
Number of subjects: 39
Study 22762536 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC catheter
Number of subjects: 104
Study 22762536 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC-free LoFric catheter
Number of subjects: 104
Study 21854282 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 255
Study 21854282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 19347752 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Norms Marketing (SNM) campaigns
Number of subjects: 0
Study 19347752 — intervention group
Group type: COMPARATOR
Intervention: Control group institutions (no SNM campaign)
Number of subjects: 0
Study 16901714 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm modified Calafiore cardioplegia (WARM group)
Number of subjects: 30
Study 16901714 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (COLD group)
Number of subjects: 30
Study 15113716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (feeding malnourished patients) for 1 month
Number of subjects: 15
Study 11795364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 9555667 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous norepinephrine (NE) at pressor doses (delta MAP = 20 mmHg)
Number of subjects: 8
Study 9555667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7995145 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (20 Gy total, divided into four daily fractions of 5 Gy each)
Number of subjects: 284
Study 7995145 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone
Number of subjects: 284
Study 7995145 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 284
Study 2908216 — intervention group
Group type: COMPARATOR
Intervention: Chlordesmethyldiazepam 0.1 mg/kg i.v. (group C)
Number of subjects: 16
Study 2908216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental 5 mg/kg i.v. (group T)
Number of subjects: 16
Study 30760241 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 72
Study 30760241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29790420 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory Training (OT)
Number of subjects: 42
Study 29790420 — intervention group
Group type: COMPARATOR
Intervention: Control group (nOT)
Number of subjects: 42
Study 25848127 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the true point
Number of subjects: 60
Study 25848127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) acupressure
Number of subjects: 60
Study 24646366 — intervention group
Group type: COMPARATOR
Intervention: Daily interval training until a 25% decrement in time-to-fatigue performance (Study 1)
Number of subjects: 0
Study 24646366 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (Study 2)
Number of subjects: 0
Study 24646366 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS scores obtained over a 2-week period before swimming competitions (Study 3)
Number of subjects: 0
Study 22505376 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical isosorbide dinitrate 10%
Number of subjects: 75
Study 22505376 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical isosorbide dinitrate 5%
Number of subjects: 75
Study 22505376 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatments (control group)
Number of subjects: 75
Study 22505376 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive patients (5 years later)
Number of subjects: 75
Study 20200547 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) ± Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 20200547 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 17613297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (5 pmol/kg/min) infusion
Number of subjects: 16
Study 17613297 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 16
Study 16040670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on goal attainment scaling
Number of subjects: 201
Study 16040670 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 11122834 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative preparative regimens
Number of subjects: 116
Study 9054905 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrist/primary care model
Number of subjects: 0
Study 9054905 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrist/psychologist team model
Number of subjects: 0
Study 8335833 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (sulfhydryl‐containing angiotensin‐converting enzyme inhibitor)
Number of subjects: 0
Study 8335833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerin (1‐ to 20‐micrograms doses)
Number of subjects: 0
Study 8335833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2445091 — intervention group
Group type: EXPERIMENTAL
Intervention: YM-12617 (0.2 mg)
Number of subjects: 82
Study 2445091 — intervention group
Group type: EXPERIMENTAL
Intervention: YM-12617 (0.4 mg)
Number of subjects: 82
Study 2445091 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study 2967855 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (0.3 micrograms/kg per min)
Number of subjects: 12
Study 2967855 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (0.1 microgram/kg per min)
Number of subjects: 12
Study 2967855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum analytes at 6 and 14 days post-injury
Number of subjects: 16
Study 31517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitinase‐3‐like protein 1
Number of subjects: 16
Study 31517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor binding protein 1
Number of subjects: 16
Study 31517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor binding protein 5
Number of subjects: 16